ProMIS Neurosciences is trading 8.51% up in pre-market at $15.18, after rising from the August 27 close of $13.99; no company-specific announcement dated August 28, 2026, was identified in available reliable coverage.

  • The latest official update was the August 13 second-quarter report.
  • Positive PMN310 interim Alzheimer’s safety and biomarker data were announced July 28.
  • Those earlier developments do not clearly explain the current pre-market move.